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Reﬂecting on My Time as Editor-in-Chief
Timothy J. O’Leary, M.D., Ph.D.From the Department of Veterans Affairs, Washington, District of Columbia (Editor-in-Chief)As my term as Editor-in-Chief comes to an end, it is natural
to reﬂect on the course that the Journal and the ﬁeld of
molecular pathology has taken throughout the past 5 years.
The ﬁrst issue of The Journal of Molecular Diagnostics
(JMD) in 1999 featured papers on single-gene in situ hy-
bridization. The January 2010 issue of the Journal, the ﬁrst
issue of my tenure, featured state-of-the-art single gene real-
time PCR methods as well as advanced array-based di-
agnostics, with both techniques able to address genetics,
hematopathology, solid tumors, and infectious diseases.
Introduction of the microarray, whether used for DNA
sequence analysis or for quantitative assessment of RNA
expression, represented the leading edge of technology in
the diagnostic laboratory at that time. Although these tech-
nologies remain a part of the diagnostic armamentarium,
analysis of recent issues demonstrates that community
attention has shifted to miRNAs and next-generation
sequencing. It is nothing short of amazing to me to see
whole genomes sequenced in less time than it took us to
sequence a single translocation/fusion region when the
Journal ﬁrst began publication.
Although the technology of molecular diagnostics has
changed, the responsibility of the Journal to “ﬁrmly estab-
lish the clinical validity and utility of molecular diagnostic
methods,” as I articulated in my initial editorial,1 has not
wavered. In the last 5 years, we have increased the rigor
with which analytical and clinical validity and utility are
demonstrated in the Journal. JMD no longer publishes
single case reports (Consultations in Molecular Diagnostics)
and instead focuses on full-length articles. The use of
discrepant analysis in computing sensitivity and speciﬁcity
is no longer acceptable, as the technique results in statisti-
cally biased estimates. Instead, authors are now required to
compute 95% conﬁdence intervals for sensitivity, speci-
ﬁcity, and similar quantities to help readers understand
limitations in the conclusions that can be reached when
sample sizes are small. Furthermore, authors are required to
use formal statistical testing when drawing conclusionsCopyright ª 2014 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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http://dx.doi.org/10.1016/j.jmoldx.2014.09.001about the relative performance of laboratory tests, Bonferroni
corrections for testing multiple hypotheses when appropriate
and power analysis to support sample size selection. Finally,
the use of formal statistical reviews has been signiﬁcantly
increased, and several statisticians have been added to
the Editorial Board. These efforts, strongly supported by
members of the Editorial Board, have had a signiﬁcant
impactdpublished versions, not infrequently, have different
conclusions from those originally suggested by the authors. I
believe that these efforts have dramatically increased the
quality and reliability of papers published in the Journal.
Our efforts to improve the statistical rigor of JMD papers,
though not insigniﬁcant, are dwarfed by the efforts of au-
thors, reviewers, and editors to assure scientiﬁc quality.
JMD authors are dedicated and patient, often submitting
multiple revisions before ﬁnal acceptance of scientiﬁcally
meritorious work. JMD reviewers, some of whom review
more than 10 papers each year, read each submission
carefully to assure not only that the conclusions are signif-
icant and supported by the data but also that the paper can
be understood by the reader. Senior Associate Editor Bar-
bara Zehnbauer not only handles individual papers but has
also successfully ﬁlled the Editor-in-Chief role for months at
a time when I was away unexpectedly. Associate Editors
Fred Barr, Angela Caliendo (retired), Adam Bagg, Victoria
Pratt, and Yi-Wei Tang have guaranteed scientiﬁc quality
through selection of world-class reviewers and by their own
rigorous review that incorporates the opinions of the re-
viewers into the conclusions they have drawn based on their
own reading of the manuscripts. In addition, Reviews Editor
Marc Ladanyi has ﬁlled the role of soliciting review papers
and vetting their scientiﬁc quality before acceptance. Their
efforts have made publication in JMD much more selective,
with the acceptance rate for Regular Articles dropping from
51% in 2009 to 28% in 2013 and the impact factor
increasing to 3.955.2
The efforts of the Associate Editors and the Editorial
Board would have failed without the incredible expertise
O’Learyand dedication of Managing Editor Audra Cox, Assistant
Managing Editor Emily Essex, and Scientiﬁc Editor Chhavi
Chauhan. These individuals not only ensure that the process
of scientiﬁc review is performed proﬁciently and expedi-
tiously, but they also make sure that production of the
Journal proceeds in a timely, professional, and exception-
ally competent manner. These individuals, together with
Mark Sobel [Executive Ofﬁcer, American Society for
Investigative Pathology (ASIP), and supervisor of the ASIP
Editorial Ofﬁce], successfully navigated the 2011 migration
to Elsevier as publisher in a way that was effortless from the
perspective of the Editors, pushed hard to make sure that all
past content is available 24/7 in electronic form, and suc-
ceeded in formulating workﬂows that allow accepted arti-
cles to appear online (as uncorrected proofs) shortly after
acceptance. These efforts, supported by the staff of both the
Association for Molecular Pathology (AMP) and ASIP and
by the Joint Journal Oversight Committee, have been a
major reason why The Journal of Molecular Diagnostics is
considered a top-tier Pathology journal, having grown in
inﬂuence alongside its expanding readership, particularly
members of AMP (see the twentieth anniversary Guest
Editorial by Dan Farkas in this issue).3594Serving as Editor-in-Chief has been a great privilege for
which I thank AMP and ASIP. I offer my greatest thanks to
the Associate Editors, the Editorial Board, and Journal Of-
ﬁce staff, who carry the bulk of the Journal’s load. Their
willingness not only to tolerate my shortcomings but also to
go above and beyond the call of duty with every paper, and
every issue, has been truly inspiring for me. These in-
dividuals are not only great molecular pathologists and ed-
itors but are truly great human beings. I am greatly honored
to have had the chance to work with them. As we welcome
Barbara Zehnbauer into her new role as Editor-in-Chief in
January 2015, I have little doubt that they will provide the
support necessary for her to continue the path of excellence
that was forged by Karen Kaul during JMD’s ﬁrst 11 years.References
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